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The management of lymph nodes in nonmelanoma skin cancer patients is currently still debated. Merkel cell carcinoma (MCC),
squamous cell carcinoma (SCC), pigmented epithelioid melanocytoma (PEM), and other rare skin neoplasms have a well-known
risk to spread to regional lymph nodes. The use of sentinel lymph node biopsy (SLNB) could be a promising procedure to assess
this risk in clinically N0 patients. Metastatic SNs have been observed in 4.5–28% SCC (according to risk factors), in 9–42% MCC,
and in 14–57% PEM. We observed overall 30.8% positive SNs in 13 consecutive patients operated for high-risk nonmelanoma skin
cancer between 2002 and 2011 in our institution.These high rates support recommendation to implement SLNB for nonmelanoma
skin cancer especially for SCC patients. Completion lymph node dissection following positive SNs is also a matter of discussion
especially in PEM. It must be remembered that a definitive survival benefit of SLNB in melanoma patients has not been proven yet.
However, because of its lowmorbidity when compared to empiric elective lymph node dissection or radiation therapy of lymphatic
basins, SLNB has allowed sparing a lot of morbidity and could therefore be used in nonmelanoma skin cancer patients, even though
a significant impact on survival has not been demonstrated.
1. Introduction
20 years ago [1], sentinel lymph node biopsy (SLNB) was
introduced for melanoma patients and later for numerous
other tumors with lymphatic metastatic propensity. Even
though surgical oncology community is divided in believers
and nonbelievers regarding its application, data show that
SLNB has already changed the treatments modalities in
melanoma and breast cancer patients, at least with respect
to TNM classification. It has allowed a better understanding
of disease progression and response to treatment in patients
with comparable staging groups.
Nonmelanoma skin cancer with potential metastatic
spreading to regional lymph nodes regroups skin lesions
like high-risk squamous cell carcinoma (SCC), Merkel cell
carcinoma (MCC), and pigmented epithelioidmelanocytoma
(PEM). Because of the low incidence of nonmelanoma skin
cancer with potential metastatic spread and the lack of
large clinical trials, the use of SLNB in these cases is not
well established, and no guidelines are currently available.
Previous studies conducted about this subject reported a
high rate of positive sentinel nodes (SNs) in nonmelanoma
skin cancer: 4.5–28% for SCC [2–4], 16–42% for MCC [5–
7], and 14–46% for PEM [8, 9]. In this context, the role of
SLNB in nonmelanoma skin cancer should be accepted as a
standard staging procedure assuming that N status is a strong
predictive factor for survival.
2. Material and Methods
Over a 10-year period from January 2002 to December
2011, a total number of thirteen patients underwent a SLNB
for nonmelanoma skin cancer at the University Hospital
of Lausanne, Switzerland. The patients were identified and
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registered in parallel of a melanoma patients’ registry (550
SLNB during the same time), and a retrospective analysis
was performed. Data were retrieved form patient’s files and
imaging database. The study protocol and data collection
were approved by our audit department.
Based on established protocol published earlier [10], a
triple technique was used to identify SNs. Briefly, a 99m Tc
nanocoll lymphoscintigraphy was performed preoperatively
(day before or same day), followed by intraoperative injection
of 2mL. patent blue V intradermally around the primary
tumor or in the scar. SN was localized using hand-held
gamma-probe guidance. Histopathology followed standard-
ized analysis for melanoma patients: serial sectioning, H.-E,
and corresponding immunohistochemistry (S100 protein and
Melan-A or cytokeratins)
Data retrieved included demographics, type of primary
tumor, number of SN removed, number of positive SNs,
completion lymph node dissection (CLND), nonsentinel
lymph nodes (NSNs), and oncological followup including
local recurrence, lymphatic extension, metastasis, disease-
free, and overall survival.
The aim of our present study was to analyze the rate
of positive SNs and reliability regarding false negative rate
during followup in nonmelanoma skin cancer patients in our
series and compare our data with a review of the current
literature.
3. Results
3.1. Patient’s Demographics. Thirteen patients with non-
melanoma skin cancer underwent SLNB. Of these, eight
presented a squamous cell carcinoma (SCC), three a Merkel
cell carcinoma (MCC), and two a pigmented epithelioid
melanocytoma (PEM). The median age was 68 years (range
25–92 years; mean ± SD: 61.5±21.2).There were 8 males and
5 females. Clinical details are summarized in Table 1.
3.2. Biopsy Results, Outcomes of Surgery, and Followup. The
rate of positive SN for the 13 patients was 31% (4/13). The
median followup was 23 months (range 2–76 months). Fifty
SNs were removed, and 7 were positive in 4 patients.
Patient 1 with MCC of right buttock had one
micrometastatic (<2mm deposit) in 4 examined SNs.
Radiation therapy was given to the buttock and inguinal
areas. Patient 4 with MCC of the left leg had one metastatic
SN (6mm) out of 2. She refused any further adjuvant therapy.
Both MCC N+ patients are free of recurrent disease with a
follow-up period of 20 and 54 months, respectively.
Patient 7 with a high-risk SCC of left thumb had 2
metastatic SNs (1.5 cmand 1 cm) out of 3. Twodeep suspicious
nonsentinel nodes (NSNs) were also removed during the
same intervention, and one showed a 3 cm metastasis. The
patient was preoperatively investigated only by MRI of the
arm, and clinically no axillary node was palpable. ELND
was performed, and 2NSNs out of 10 were positive. He
had adjuvant radiation therapy (50Gy) and chemotherapy
(carboplatin) following axilla recurrence. Unfortunately the
patient ultimately needed an amputation with disarticulation
15 months after the diagnosis because of further progression
of the disease in the axilla. He is still alive 23 months after the
diagnosis.
Patient 11 with a deep (11mm) PEM of the middle of the
back had SLNB in both axillas. On the right side, 1 SN showed
only one capsular focus of metastatic cells and following
a second opinion of an international expertise center we
decided not to proceed with ELND. One NSN was negative.
On the left side, one SN had a parenchymal focus of PEM and
was considered positive.Three other NSNs were negative and
ELND showed 12 other negative NSNs. She had no evidence
of disease within a followup of 5 years.
Nine patients were found to be SN negative. Seven
patients had SCC: patients 6 and 13 were lost during the
followup, after 2 and 6 months, respectively. Patient 2 with
epidermolysis bullosa developed other SCC lesions on the
upper and lower limbs 9 months, respectively 4 years after
the excision of the primary tumor of the lower limb. Patient
5 with an initial SCC of the right vulva underwent an excision
of the contralateral vulva for a VIN 3 tumor 3 years later.
Patient 8 died from an aggressive locoregional progression
of the disease six months after the diagnosis. Patients 9 and
10 showed no recurrence after a followup of 9 and 15 months.
Patient 12 with PEMwas lost during followup after 11 months,
and patient 3 with MCC did not recur after a followup of 6
years.
Patient 13 presented a 3.5 cm large poorly differentiated
SCC, and lymphoscintigraphy identified four different SN
basins (3 interval nodes): humeral lateral, and medial, axilla
and cervical (Figure 1). All 7 SNs were negative.
Overall no postoperative complication at the SLNB site
was registered. No patient with negative SN had a nodal
recurrence.
4. Discussion
Our experience confirms results of other series regarding
feasibility and reliability (false negative rate) of SLNB. This
cohort of patient with heterogeneous group of rare primary
skin carcinomas reflects the experience in the literature. The
rate of 30.8% positive SNs observed in the current study is
comparable to those of similar studies published on non-
melanoma skin cancer patients. For instance, Cecchi et al.
[18] and Wagner et al. [19] reported a rate of positive SNB of
20% (2/10) and 31.8% (7/22), respectively. Of note, majority
of series describe a pretty limited number of patients. In
our own study, patients who were SN positive or negative
had no nodal recurrence and disease recurred or progressed
regionally independently of SN status (one patient in each
group of SN positive or SN negative).
Following potential advantages of SNB must be under-
lined.
(1) Detection of regional lymph node basins at risk for
N+ status: lymphatic mapping using lymphoscintig-
raphy is useful in defining lymphatic basins at risk,
which is very important in complex lymphatic net-
work in head and neck surgery for example [20].
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Figure 1: Patient 13 had a 3.5 cm large poorly differentiated SCC on the dorsal side of left hand that was reaching subcutaneous level
with perineural invasion but with no lymphovascular invasion. Dynamic lymphoscintigraphy of the upper left limb demonstrated multiple
drainage pathways on the dynamic views (a), and accessories lymph nodes were immediately visualized in the humeral lateral and medial
regions (red arrows). These were confirmed not to be only ectatic lymphatic vessels but 2 different sentinel nodes corresponding to 2 basins
(b). Delayed views of the arm and shoulder (c, d) showed 2 more SNs in 2 basins: in the axilla (blue arrow) and basicervical (green arrow).
All 7 SNs in 4 basins were negative.
Table 1: Patient characteristics, sentinel lymph nodes results, and followup.
Patient Age Sex Type Primarysite SLN region Risk factor
SLN
total
SLN+ Clearance Adjuvanttherapy
Follow-up
(months) Recurrence
1 78 M Merkel Buttock Inguinal 4 cm large 4 1 No Yes 20 No
2 39 M SCC Leg Inguinal EBD 3 0 No No 75 No
3 72 M Merkel Buttock Inguinal 2.2 cm large 2 0 No No 76 No
4 84 F Merkel Leg Inguinal LVI 4 1 No No 54 No
5 33 M SCC Vulva InguinalIliac
2 cm large
7mm deep 3 0 No No 52 No
6 92 F SCC Leg Inguinal 5 cm large7mm deep 5 0 No No 2 ?
7 72 M SCC Thumb Axillary Recurrent, 3 cm largeBone infiltration 6 3 Yes Yes 23 Yes
8 51 F SCC Thigh Iliac Chronic scar 3 0 No Yes 6 Yes
9 83 M SCC Leg Inguinal 1.7 cm large5mm deep 1 0 No No 15 No
10 61 F SCC Forearm Axillary Chronic scar 3 0 No No 9 No
11 25 F PEM Back AxillaryBilateral 11mm deep 7 1 Yes No 61 No
12 46 M PEM Back AxillaryBilateral Other skin carcinoma 3 0 No No 41 ?
13 68 M SCC Hand Humeral twiceaxillary, cervical
3.5 cm large
Poor differentiation 7 0 No No 6 ?
EBD: epidermolisis bullosa dystrophyca, LVI: lymphovascular invasion.
(2) Staging of real N0 patients, in whom unnecessary
CLND or radiation therapy and their significant
morbidity can be spared, meaning that false negative
assessment (CLNDor node recurrence during follow-
up) must be as low as possible. It should be assumed
that removing early metastatic node improves sig-
nificantly the prognosis compared with removing
advanced nodal disease.
(3) Detection of metastatic and micrometastatic diseases
in clinically and radiologically N0 patients. Over-
staging is possible (uncertain meaning of isolated
tumor cells), but false negative N0 patients (clinically
negative and H-E negative) can be detected and their
staging is correctly assessed for directing appropriate
treatment.
(4) Detection of interval SNs (lymph nodes outside usual
basins) that are at the same metastatic risk as other
SNs and that can be otherwise misinterpreted as in-
transit metastases [10, 17, 21–23] (Figure 1).
On the other hand SNLB has a price: a hospital stay and
surgery and its own morbidity. Adverse effects of SLNB were
observed in 25% compared with 70% with SLNB and CLND
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Table 2: Criteria for high-risk cutaneous squamous cell carcinoma
[12, 22, 24–26].
Histopathologic factors
Size >2 cm
High-risk location (head and neck)
In-transit metastatic lesion
Poor differentiation
Perineural invasion
Tumour thickness >5-6mm
Desmoplastic growth
Other factors
Radiation field
Patients with immunosuppression (transplantation and others)
Recurrence
Multiple SCCs
Marjolin’s ulcer (carcinoma in burn scar or chronic ulcer)
in the Z0011 breast cancer trial (6% lymphedema versus 11%
at one year) [24]. In the Sunbelt Melanoma Trial overall
morbidity was 4.6% for SLNB alone compared with 23.2%
for SLNB andCLND. Lymphedema following SLNBwas 0.3%
in the axilla and 1.5% in the groin [25]. Incidence of adverse
reactions to different blue dyes used for SLNB is 1–3% [26].
5. Squamous Cell Carcinoma (SCC)
SCC represents the second most frequent skin cancer after
melanomas [3, 4] and its incidence in the population reaches
approximately 1% [4]. Incidence of SCC varies widely accord-
ing to patients’ risk like sun exposure or immunosuppression.
Most of these patients will not develop nodal disease, but
in some patients it represents the first metastatic step. The
reported metastatic rate of high-risk SCC reaches 11–47.3%
[27], and the regional lymph nodes are the first involved.
Patient with clinical detectable nodal metastasis has a poor
prognosis with a reported 5-year survival rates of 26% [27].
Risk factors for metastasis or local recurrence of SCC
have been described in the literature and are summarized
in Table 2 [19, 28–31]. They should be used to select patients
eligible for SLNB. Despite the absence of controlled studies,
guidelines about the staging for high-risk SCC in immuno-
suppressed patients or patients planned for a transplantation
recommend to perform a SLNB [32].
Recently the French Dermatology Recommendations
Association (aRED) suggested a prognostic classification
including 2 groups defined as low-versus-significant
metastatic risk [33]. Unlike previously published guidelines
reviewed by Veness [29] that proposed no recommendation
for the management of lymph nodes in high-risk patients,
aRED stated that SLNB may be envisaged for clinical trials
and evaluation studies. Their proposal was ultrasound
surveillance and no routine ELND or radiation therapy [33].
The low rate of false negative SLNB reported in the
literature [2, 34] is an essential quality marker for SLNB
efficacy. False negative rate seems to depend on SCC location:
all sites 15.4%, head andneck 0% and truncal/extremity 22.2%
[35]. In the absence of consensus in high-risk SCC patients,
46% of surgeons proposed SLNB in Jambsaria-Pahlanjani’s
survey [36].
They are only a few studies published about high-risk
patients presenting SCC arising from a burn scar or a chronic
ulcer (Marjolin’s ulcer) [22, 37] (patient 8), locally recurrent
SCC [38], and patients with recessive-type epidermolysis
bullosa (patient 2) [39].
6. Merkel Cell Carcinoma (MCC)
MCCs are rare and aggressive neuroendocrine tumors aris-
ing from cutaneous Merkel cells. Their incidence seems to
be rising; they affect more elderly and immunosuppressed
peoplewith a correlation to sun exposure.They tend to spread
locally before developing distant metastasis, and at time of
diagnosis up to 68% of patients already present lymph node
involvement [40]. The presence of clinically palpable nodes
and visible lymphadenopathy on CT scan is an indicator of
poor survival rate [13] so that early detection of lymph node
involvement is the most important prognostic factor.
MCC is known to be radiosensitive, but the systematic
use of radiotherapy to the primary tumour and/or the lymph
node basin is still debated. Eich et al. [41] have reported a
significant higher disease-free survival rate and Mojica et al.
have reported [42] a higher overall survival rate after adjuvant
radiotherapy. However, Allen et al. could not demonstrate
that an adjuvant radiotherapy was necessary if the primary
tumor and the lymph node basin were surgically controlled
(ELND, SLNB, andCLND) [5]. Conversely in patient without
nodal control (SLNB/ELNB) metastatic lymph node will
appear in 45% of cases and radiotherapy is mandatory.
Already in 2002, Goessling et al. listed 49 patients with
MCC and concluded that the SLNB could be a useful tool
for their staging [43]. Since then, the use of SLNB for MCC
has been the subject of several reviews which are summarized
in Table 3 [5, 7, 11–17]. The cumulated rate of positive SNs
was 31% (101/326). Only half of the SN positive patients
underwent a CLND, and the rate of positive NSNs after
CLND was 35% (19/54). It seems that despite the absence
of guidelines, the number of patients undergoing SLNB
followed by CLND is increasing.
Criteria for a high risk of metastatic sentinel node in
Merkel cell carcinoma are presented in Box 1. However,
patients without these criteria still have a 23–36% risk for
positive SN [41, 42, 49].
One of the largest monocentric study was presented by
Fields et al. [16]. From 153 patients who underwent SLNB,
45 of them presented positive SN. CLND was consecutively
performed in 21 patients, and 6 of them presented metastatic
NSNs. During a median followup of 41 months 8/99 SN-
negative patients developed nodal recurrence which cor-
responds to a false negative rate of 15%. The presence of
lymphovascular invasion (LVI) was highly predictive for the
disease-free and overall survival but not for the SN status.
Interestingly 71% of the patients with positive SN and 92%
of the patients with negative SN did not receive any adjuvant
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Table 3: Review of studies with sentinel lymph node biopsy in patients with MCC.
Author ReferenceNumber Year
patients
with SLNB
H-E
± IHC +SN CLND + NSN
Nodal
recurrence in
SN patients
Median
followup
(months)
Allen et al. [5] 2005 54 NS 12 8 2 Not detailed∗ 40
Maza et al. [11] 2006 23 Both 11 8 4 2 36.1
Gupta et al. [7] 2006 30/61 Both 7 ? — Not detailed —
Ortin-Perez
et al. [12] 2007 8 Both 3 3 0 0 55
Warner et al. [13] 2008 11/17 Both 3 2 ? 5 16
Shnayder et
al. [14] 2008 10/15 Both 4 1 1 1 24
Bajetta et al. [15] 2009 21/95 NS 8 8 4 65
Fields et al. [16] 2011 153 Both 45 21 6 8/108 41
Howle and
Veness [17] 2012 16 Both 8 3 2 2/8 19.5
Total 326 101 54 19
∗One out of 21 SN negative patients results published in a previous article (20) with a median followup of 19 months.
NS: not specified.
Greatest horizontal diameter ≥3.75mm
Histopathologic factors
Infiltrative tumour growth pattern
Mitotic rate >10
Size > 1 cm/>2 cm
Tumour thickness >2mm
Box 1: Criteria for a high-risk of metastatic sentinel node in Merkel
cell carcinoma.
therapy. In this study, the author recommends to perform
routinely SLNB even by patients who are clinically staged
as N0. However, this staging procedure remains a subject of
controversies in the recent published studies [15, 44, 45].
The use of immunohistochemistry (pancytokeratin and
CK-20 antibodies) can significantly upstage false negative
SNs [46, 47] and should be the role for SN examination.
In summary up to 68% of MCC patients present nodal
metastases at time of diagnosis. 20–30% of clinically N0
patients can be upstaged if a SLNB is performed. Nodal status
is an important prognostic factor. The exact role and benefit
of radiation therapy on lymphatic basins are not definitively
assessed (clinically negative or after SLND, CLND, and
ELND) [5, 13, 14, 42]. New attempts for improving standard-
ized histopathology report [48] and treatment algorithm [49]
would be helpful.
MCC has a higher incidence in transplanted patients.
These patients are younger and their 5-year overall survival
of 46% [50] is slightly lower than the 54% observed in a large
MCC data base regarding matched population [51].
7. Nonmelanoma Pigmented Tumors
Some patients with Spitz naevi may present with a difficult
differential diagnosis for other melanocytic tumors including
melanoma. A review of the literature about spitzoid tumors
showed that 37.7% of patients presented metastatic SNs,
and 14% of the patients with CLND had metastatic NSNs
[52]. Metastatic propensity will define malignancy, but in
SN negative patients only the followup can exclude it. These
results were published by Magro et al. who reviewed their
experience with SLNB in borderline melanocytic tumors
(BMTs) [9].
Pigmented epitheloid melanocytoma, also called equine
or animal-type melanoma, is a rare melanocytic tumor with
frequent metastatic spreading to local lymph nodes and
occurs mainly during childhood and in young adults [8].
However, Mandal et al. observed that patients with
positive SN had an excellent outcome. They concluded that,
while sparing risk for progressive bulky metastatic lymph
node, SLNB would not change the prognosis in this low-
grade melanocytic neoplasm. As no high-risk PEM has been
identified, simple surveillance of the lymphatic basin with
ultrasound seems to be a safe solution [53].
8. Other Rare Skin Neoplasms
SLNB has also been evaluated for cutaneous apocrine ade-
nocarcinoma [54] and for aggressive digital papillary adeno-
carcinoma [55]. As both of them have a high propensity for
lymphatic invasion, the systematic use of SLNB should be
recommended.
Because of their lymph node metastatic risk, some soft
tissue sarcomas may also been concerned by SLNB. Lymph
node dissection is recommended in clinically or radiologi-
callyN+ patients [56], but the role of SNBhas not been clearly
established yet.
Lymph node metastatic rate for epithelioid sarcoma and
angiosarcoma ranges from 17 to 80% and 11 to 40%, respec-
tively.
Regarding skin lymphomas a large recent series of
patients with mycosis fungoides and Sezary syndrome
6 Journal of Skin Cancer
showed that 91% of patients are clinically N0 [57]. As TNM
plays a role in prognosis and treatment, SLNB could find
its place for detecting patients with early stages (IA-IB) who
adversely progress. In cutaneous T-cell lymphoma, SLNB can
prove the primary cutaneous origin and avoid a systemic
treatment [58].
9. Conclusion
Management of high-risk nonmelanoma skin tumor patients
is still a matter of debate in the absence of randomized
trials. Randomized studies are difficult to conduct because
of the rarity of these tumors; the best option is therefore
to pool these patients in multicentric cohort in order to
support the guidelines defined by consensus. Definition of
high-risk parameters and standardization of examination
protocols could allow such studies of these rare but life-
threatening malignancies. SLNB has its price and has its own
morbidity; it represents, however, the best way for assessing
N stage in clinically and radiologically negative patients.
It must be remembered that a definitive survival benefit
with SLNB in melanoma patients has not been proven (yet)
and is currently evaluated by the MSLT 2 trial. However,
because of its low morbidity compared with empiric ELND
or radiation therapy on lymphatic basins, SLNB has already
spared a lot ofmorbidity inmany patients, before this survival
advantage can also be demonstrated in nonmelanoma skin
cancer patients. Thus, until better data demonstrate the
opposite, SLNB should be recommended in nonmelanoma
skin tumors.
Abbreviations
SLNB: Sentinel lymph node biopsy
CLND: Completion lymph node dissection
ELND: Elective lymph node dissection
MCC: Merkel cell carcinoma
SCC: Squamous cell carcinoma
PEM: Pigmented epithelioid melanocytoma
SN: Sentinel lymph node
NSN: Nonsentinel lymph node.
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